📈 Join us for LIVE TRADING action all day long in the 📈

 Market Master’s trading room

Now, at absolutely no cost to our readers

Just one click, and you’re in!


The markets have been powering higher, and I have had a good read on the current trend.

Besides some big wins with my paid services, some of the recent stocks I shared with everyone have done extremely well.

Just last week, I shared my thoughts on a small biotech stock that has been one of the best performers of the year.

I said that it was looking primed for a move, and it made a 20% move higher by the next day.  In fact, today, it is touching its 52-week high.

On Friday last week, I had a “technical alert” on a small commodities company that was lighting up with chatter from traders.  

That stock went on to move nearly 40% higher in just the opening hour of trading and is still grinding higher.

While trading isn’t easy right now, I have continued to find winning ideas.

And today, I have another big play for you to look at.

Pull up NeuroOne Medical (NMTC) on your platform right now.

This is a sleepy little stock that has a tendency to spring back to life and make fast moves.

I’ve mentioned it a few times in the past, and if you recall, we’ve seen some very nice trades from it.  

It’s all about waiting for the right signals, and we just got one of my favorites – a new “GO” trend on the hourly chart (see below)

📈Levels to watch:

On the downside, I would keep a close on the support level around $1.12, which NMTC has bounced off of several times in the last couple of weeks.

I definitely don’t want to see that broken.

On the upside, I think that $1.24 is the first important target, since that was the recent high that was rejected a couple of days ago.

If NMTC can trade above that, then the next level to watch is $1.35, which is where the stock started to hit resistance last month.

After $1.35, things could really heat up.  If the stock starts to trade above that, I’ll update what I see on a techncial level.

On top of the “GO” signal that was recently fired, there are some other great catalysts that could drive NMTC right now.

Insider buying is a big driver of future prices, and yesterday, this news came out…

I always say that insiders can sell for a lot of reasons… they only buy for one – they think it is going higher.

When I am in doubt about what to do with a stock, I will often follow the strongest insider buying patterns (and there are not many of them right now!)

The next thing you should look at is the fact that NMTC is “making the rounds” on business TV lately.

They are starting to talk to the media about their cutting-edge medical technology now. 

Here is a recent clip of NMTC talking on Bloomberg…

So what does the company do?

NeuroOne Medical Technologies Corp (NMTC) is a medical technology developer of electrodes designed to diagnose and treat a variety of neurological conditions, including epilepsy, Parkinson’s disease, and chronic back pain.

Despite being a relatively small company, NMTC has received FDA clearance for three of its devices and has forged powerful partnerships with the likes of the Mayo Clinic — the nation’s top-ranked hospital.

NMTC’s clinical partnership with the Mayo Clinic began in 2017, and the first commercial human use of one of NMTC’s electrodes was performed at the Mayo Clinic in November 2020.

Today, the Mayo Clinic is a shareholder in NMTC and its leading neurologist, Dr. Greg Worrell, chairs the company’s Scientific Advisory Board.

According to the company, this collaboration with the Mayo Clinic has produced “disruptive next-generation diagnostic electrodes advancing a new era in neuroscience.”

The company’s three FDA-cleared devices are:

Evo® Cortical Electrode – A device that can “monitor, record and stimulate the surface of the brain for up to 30 days.” It’s up to seven times thinner and eight times lighter than the legacy silicon-based electrodes.

These electrodes are designed to cause less trauma to the brain and therefore generate a decreased immune response, which can interfere with electrode readings.

Evo® sEEG Electrode – An advanced diagnostic device for seizure detection. It’s designed to be less invasive and to reduce the risk of “plunging” and brain damage.

The company says this electrode offers “proven placement accuracy and outstanding signal quality,” allowing doctors to “capture the vital data [they] need to support more confident diagnoses.”

OneRF™ Therapeutic Ablation Electrode System – This is a technology that pairs with the sEEG electrodes to provide therapeutic functionality in addition to the diagnostic.

Cleared by the FDA in December, this system can create radiofrequency (“RF”) lesions in nervous tissue for use in neurosurgical procedures.

NMTC formed a strategic partnership in July 2020 with Zimmer Biomet (NYSE: ZBH, ~$25B market cap) — “a worldwide leader in robotic technology used in minimally invasive neurosurgeries” — to exclusively commercialize and distribute its EVO® diagnostic electrodes.

NMTC received a $2 million upfront payment through this partnership and a $3.5 million accelerated payment for reaching an agreed-upon milestone.

For its OneRF™ system, NMTC announced a limited commercial launch on March 26, with CEO David Rosa appearing on Fox Business on April 3 to discuss the breakthrough, and to reveal that the first human implant would be done at the Mayo Clinic that month.

On April 9, we learned that the device was implanted in an epileptic patient, and the next day, David Rosa was interviewed on Bloomberg TV about what a “seismic shift” this was for the company.

Now that it has reached the commercialization stage for its electrodes, NMTC’s revenues have climbed significantly, from $171,000 in FY 2022 to $1,952,000 for FY 2023.

Bottom line: There are a lot of positive catalysts out there for NMTC right now. On the price chart, I think there is a lot of potential right now.

The price level for NMTC right now is something that can’t be ignored.

I think it is an excellent candidate, and needs to be on your watchlist right now.

To Your Success,

Jeff Bishop

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!



*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.

*PAID ADVERTISEMENT. Raging Bull has currently been paid twelve thousand five hundred dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program on may 7. 2024. Raging Bull had previously been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program on march 26. 2024. Raging Bull was also previously paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program on march 4, 2024.  Raging Bull was previously paid five thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. from a period beginning on December 12 through December 12, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NeuroOne Medical Technologies Corp., increased trading volume, and possibly an increased share price of NeuroOne Medical Technologies Corp.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NeuroOne Medical Technologies Corp., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.